Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2

to connected objects

Alternative title: Generierung und Charakterisierung von gegen SARS-CoV-2 gerichteten Antikörpern

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Notes: Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Dissertation, 2023

Keyword: Antikörper
Monoklonaler Antikörper
SARS-CoV-2

Event: Veröffentlichung

(where): Erlangen

(who): Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)

(when): 2023

Creator: Peter, Antonia Sophia

Contributor: Überla, Klaus
Nitschke, Lars

URN: urn:nbn:de:bvb:29-opus4-215292

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 25.03.2025, 1:48 PM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Peter, Antonia Sophia
Überla, Klaus
Nitschke, Lars
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)

Time of origin

2023

Other Objects (12)

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Monoclonal antibodies

A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model

Hochschulschrift

Glycoengineering of Monoclonal Antibodies

Aufsatzsammlung

Monoclonal antibodies in transplantation

Oncofetal antigen in Xiphophorus detected by monoclonal antibodies directed against melanoma-associated antigens

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Generation and characterization of novel human monoclonal antibodies directed against the hepatitis B virus

Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Monoclonal antibodies

A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model

Hochschulschrift

Glycoengineering of Monoclonal Antibodies

Aufsatzsammlung

Monoclonal antibodies in transplantation

Oncofetal antigen in Xiphophorus detected by monoclonal antibodies directed against melanoma-associated antigens

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Generation and characterization of novel human monoclonal antibodies directed against the hepatitis B virus

Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Monoclonal antibodies

A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model

Hochschulschrift

Glycoengineering of Monoclonal Antibodies

Aufsatzsammlung

Monoclonal antibodies in transplantation

Oncofetal antigen in Xiphophorus detected by monoclonal antibodies directed against melanoma-associated antigens

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Generation and characterization of novel human monoclonal antibodies directed against the hepatitis B virus

Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2

Object Details

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Monoclonal antibodies

A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model

Glycoengineering of Monoclonal Antibodies

Monoclonal antibodies in transplantation

Oncofetal antigen in Xiphophorus detected by monoclonal antibodies directed against melanoma-associated antigens

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Generation and characterization of novel human monoclonal antibodies directed against the hepatitis B virus

Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Monoclonal antibodies

A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model

Glycoengineering of Monoclonal Antibodies

Monoclonal antibodies in transplantation

Oncofetal antigen in Xiphophorus detected by monoclonal antibodies directed against melanoma-associated antigens

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Generation and characterization of novel human monoclonal antibodies directed against the hepatitis B virus

Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Monoclonal antibodies

A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model

Glycoengineering of Monoclonal Antibodies

Monoclonal antibodies in transplantation

Oncofetal antigen in Xiphophorus detected by monoclonal antibodies directed against melanoma-associated antigens

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Generation and characterization of novel human monoclonal antibodies directed against the hepatitis B virus

Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Related objects

Reset password